"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead

The Risk of Second Malignancies after Seed Migration in Prostate Cancer Patients Treated With I-125 Free Seeds Brachytherapy


Abstract

Purpose/Objective(s)

To evaluate the risk of second malignancies after seed migration in prostate cancer patients treated with I-125 free seeds brachytherapy.

Materials/Methods

Data from 2067 prostate cancer patients treated with I-125 free seeds brachytherapy in three Canadian centers were analyzed. Kaplan-Meier method was used to estimate the 5- and 7-year biochemical relapse-free and overall survival between patients who experienced or not seed migration.

Results

Mean age and Median follow-up was 64 years and 44 (range 1-147) months, respectively. Seed migration occurred in 365 of 2067 patients (17.7%). The 5-, 7-year biochemical relapse-free and overall survival for the entire cohort was 96%, 91.7% and 95.9%, 93.7%, respectively. Second malignancies occurred in 4 of 365 patients (1.1%) and 21 of 1702 patients (1.2%) in patients with or without seed migration, respectively (p=0.827). Lung cancer represented the most frequent second malignancy observed and occurred in 6 patients, all in the no seed migration group. The other second malignancies observed in the no seed migration group included: larynx (3 patients), colon (2 patients), esophagus (2), pancreatic (2), renal, myeloma, glioblastoma, non-Hodgkin’s lymphoma (1) and 2 unknown. In the seed migration group, the second malignancies observed were chronic myeloid leukemia (1), colo-rectal cancer (2) and nasopharynx (1).

Conclusion

These results do not support an increased risk of second malignancies, particularly lung cancer with seed migration after I-125 free seeds brachytherapy for prostate cancer patients. Due to the low rate of second malignancies observed in this cohort, further studies with longer follow-up are required to better correlate seed migration and second malignancies.

Poster
non-peer-reviewed

The Risk of Second Malignancies after Seed Migration in Prostate Cancer Patients Treated With I-125 Free Seeds Brachytherapy


Author Information

Eric Vigneault Corresponding Author

Radiation-Oncology, Hotel Dieu de Quebc

Kevin Martell

Radiation Oncology, University of Calgary, Calgary, Ab, Canada

Daniel Taussky

Department of Radiation Oncology, Centre hospitalier de l'Université de Montréal (CHUM)

Siraj Hussein

Radiation Oncology, Cross Cancer Center, Calgary

Guila Delouya

Department of Radiation Oncology, Centre hospitalier de l’Université de Montréal (CHUM)

Khaly Mbodji

Centre de recherche du CHU de Québec, CHU de Québec – Université Laval

Julie Piotte

Radiation Oncology, Centre hospitalier de l'Université de Montréal (CHUM)

Sindy Magnan

Medical Physics, Université Laval

Philippe Despres

Radiation Oncology, CHU de Québec – Université Laval Centre de recherche

Marie C. Lavallee

Radiation Oncology, CHU de Québec – Université Laval

Sylviane Aubin

Radiation Oncology, CHU De Québec

Luc Beaulieu

Medical Physics, Université Laval

William Foster

Radiation Oncology, CHU de Québec – Université Laval Centre de recherche

Andre-Guy Martin

Radiation Oncology, Centre Hospitalier Universitaire de Québec - L'Hôtel-Dieu de Québec, Québec, QC


PDF Print Share
Converted fe1d2eb0933311e7bc27994b300f7040 postercaro2017migration